NCT05660954 2026-04-02
CABOTHYROID
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Active not recruiting
Clinical Trials
13 trialsNCT05059470 2026-03-23
IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03109847 2025-12-11
Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Thyroid Cancers
Thomas Jefferson University
Phase 2 Terminated
NCT04623801 2025-10-08
Laser Ablation of Papillary Thyroid Microcarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06054178 2025-07-28
Identification of Nerves Using Fluorescein Sodium
Stanford University
Phase 2 Enrolling by invitation
NCT01141309 2025-07-22
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT01396733 2021-07-23
RALT
Asan Medical Center
Phase 2 Withdrawn
NCT03630120 2021-07-14
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01013597 2019-11-29
Trial of LBH589 in Metastatic Thyroid Cancer
University of Wisconsin, Madison
Phase 2 Completed
NCT04180007 2019-11-27
APT-01
Nanjing First Hospital, Nanjing Medical University
Phase 2 Unknown
NCT01025453 2018-08-15
Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00054756 2018-08-08
Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01057589 2013-09-18
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Eli Lilly and Company
Phase 2 Completed